9
Nov
2018
Sage Postpartum Depression Drug Passes Scrutiny, Blavatnik’s $200M Beneficence, & A Novartis Pricing Trial Balloon
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account. 
Share:
2
Nov
2018
Illumina Takes Out PacBio, AbbVie’s Pre-Emptive Price Cut, & HHS Drug Pricing Guy Dies
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
1
Nov
2018
Exploring Synthetic Lethal Cancer Drug Discovery: Barbara Weber on The Long Run
Today’s guest on The Long Run podcast is Barbara Weber. She is the CEO of Cambridge, Mass.-based Tango Therapeutics. Ever hear the saying ‘it takes two to tango?’ That’s where this startup draws its inspiration. It’s seeking to discover and develop synthetic lethal cancer drugs. These are intended to target two molecular vulnerabilities of a cancer cell, not just one,...Read More
Share:
30
Oct
2018
Nine VCs Who Matter, But You Never Read About
Venture capitalists see a steady stream of people asking for money and currying favor. This can inflate the ego to unhealthy proportions. The best VCs, however, don’t let all that get to their head. They also don’t just write checks. They help entrepreneurs. Quite a few of the best VCs in biotech tend to work behind the scenes. You don’t...Read More
Share:
26
Oct
2018
Amgen’s Price Cut, Biogen-Eisai Alzheimer’s Whiff, & a New Osteoarthritis Drug
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
19
Oct
2018
Novartis’ $2B Takeover of Endocyte, Revolution-Warp Drive, & Amgen’s Foray in DNA Sequencing
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
18
Oct
2018
AbbVie Plunks Down $100M Upfront for Morphic’s Oral Integrin Inhibitors for Fibrosis
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
17
Oct
2018
Making it Easy to Share Biological Data: John Wilbanks on The Long Run Podcast
John Wilbanks is today’s guest on The Long Run podcast. He’s the chief commons officer of Sage Bionetworks. He’s also a senior fellow with FasterCures. Sage, for those unfamiliar, is a nonprofit biomedical research organization, founded in Seattle in 2009 by a couple of veterans of Merck. Co-founders Stephen Friend and Eric Schadt recognized that no single company’s R&D labs,...Read More
Share:
12
Oct
2018
Allogene’s Megabucks IPO, CVS-Aetna Muscling Through, & Consumer Genetics in the Mainstream
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
11
Oct
2018
The MIT Biotech Group Alumni: Where Are They Now?
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
5
Oct
2018
Nobel Highlights and Lowlights, MSK Fallout Continues, Pfizer CEO Stepping Down
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
3
Oct
2018
Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run
Today’s guest on The Long Run is Sabah Oney. He’s the chief business officer of South San Francisco-based Alector. You could be excused if you’ve never heard of Alector or Sabah Oney. Neither makes a lot of noise. But Oney is an up-and-comer, and the company has been on my radar for some time. Alector is a serious drug discovery...Read More
Share:
28
Sep
2018
Roche’s PD-L1 ‘Practice-Changer,’ J&J Dumps Geron, and Amarin’s Fish-Oil Surprise
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
21
Sep
2018
WuXi Eyes A Fresh $1B, California Aims at AbbVie, and MSK’s Industry Ties in the Spotlight
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
19
Sep
2018
Health Data That Can Meet Pharma Standards: Amy Abernethy on The Long Run
Amy Abernethy is the latest guest on The Long Run podcast. Amy is the chief medical and chief scientific officer of Flatiron Health in New York City. She’s an MD/PhD, and previously was a tenured professor at Duke University. She made a name for herself there with more than 400 peer-reviewed publications. She honed her ideas there around using technology...Read More
Share:
14
Sep
2018
Baselga Brouhaha, a Shkreli Imitator, and Autoimmunity Strides from BMS and Gilead
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
5
Sep
2018
Telling Biotech Stories on TV: Listen to Meg Tirrell on The Long Run Podcast
Today’s guest on The Long Run is Meg Tirrell. Meg is the biotech and pharmaceuticals reporter at CNBC. This is a big job. People that control billions in investment dollars regularly keep an eye on the cable TV investment channel for breaking news and analysis on interest rates, the stock market, currencies and more. Meg makes sure they get timely,...Read More
Share:
5
Sep
2018
Fulcrum Gets $80M to Test Small Molecules Against Rare Disorders of Gene Expression
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
28
Aug
2018
Time and Money: What Are They Worth to a Young Scientist?
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
24
Aug
2018
Exact Goes from Madison Wis. to Madison Ave. & IPO Candidates Get in Line
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
